03.16.15
NantWorks, Inc. and Sorrento Therapeutics, Inc. have entered a collaboration agreement to discover and develop anti-cancer immunotherapies from Sorrento's G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' pan-omics based, precision medicine approach.
NantCell, LLC, a NantWorks company, will have exclusive license to certain antibodies and CAR-TNK products in exchange for $10 million in cash and $100 million in NantCell's equity. Sorrento will also have a share of all future profits resulting from the collaboration.
In December 2014, Sorrento and NantWorks formed the joint venture, NantiBody, LLC to develop a Phase III antibody from NantCell and a portfolio of preclinical immuno-oncology and bispecific antibodies, and ADCs, from Sorrento. NantiBody is to be funded with $100 million from NantWorks and Sorrento.
"We are excited to be working with NantWorks again," said Dr. Henry Ji, president and chief executive officer of Sorrento. "Through these strategic alliances, we are accelerating the development of our diverse portfolio of fully human monoclonal antibodies into the clinic. In addition, we will be spearheading the discovery and development of immunotherapies against neoepitopes of tumor-specific antigens."
"We are pleased to expand our working relationship with Sorrento. Our innovative collaborations will unite Sorrento's capability to develop immunotherapies with NantCell's proprietary pan-omics, bioinformatics, and precision medicine technologies," said NantWorks founder Dr. Patrick Soon-Shiong. "We are committing significant resources to the development of truly novel cancer immunotherapies, an area of significant unmet need."
NantCell, LLC, a NantWorks company, will have exclusive license to certain antibodies and CAR-TNK products in exchange for $10 million in cash and $100 million in NantCell's equity. Sorrento will also have a share of all future profits resulting from the collaboration.
In December 2014, Sorrento and NantWorks formed the joint venture, NantiBody, LLC to develop a Phase III antibody from NantCell and a portfolio of preclinical immuno-oncology and bispecific antibodies, and ADCs, from Sorrento. NantiBody is to be funded with $100 million from NantWorks and Sorrento.
"We are excited to be working with NantWorks again," said Dr. Henry Ji, president and chief executive officer of Sorrento. "Through these strategic alliances, we are accelerating the development of our diverse portfolio of fully human monoclonal antibodies into the clinic. In addition, we will be spearheading the discovery and development of immunotherapies against neoepitopes of tumor-specific antigens."
"We are pleased to expand our working relationship with Sorrento. Our innovative collaborations will unite Sorrento's capability to develop immunotherapies with NantCell's proprietary pan-omics, bioinformatics, and precision medicine technologies," said NantWorks founder Dr. Patrick Soon-Shiong. "We are committing significant resources to the development of truly novel cancer immunotherapies, an area of significant unmet need."